Vaginal Cancer Clinical Trials
Vaginal cancer clinical trials represent a crucial step in making new treatments available for widespread use. Once a promising new treatment has been identified and developed, it is then compared to the current standard of care. Clinical trials allow researchers to determine if a new therapy is more effective than the current option, or if it can produce comparable outcomes with fewer side effects.
- Which imaging techniques can help determine if lymph nodes should be removed
- Whether stem cell transplants are beneficial in the treatment of recurrent vaginal cancer
- How nutritional supplements can help counteract the side effects of chemotherapy
- Which chemotherapy drugs and combinations of drugs are most effective for late-stage cancers
Other trials have focused on developing more effective ways to use existing treatments. For instance, one previous trial studied the outcomes of patients with specific DNA mutations who received external beam radiation therapy as part of their treatment. Now, oncologists can use the information gathered during this study to create more effective radiation therapy plans for patients who possess these unique genetic characteristics.
At Moffitt Cancer Center, we have been nationally recognized for our commitment to translational research. Many of the breakthroughs we’ve achieved in our labs have been fast-tracked into exciting new treatments; as a result, we’ve been named a Comprehensive Cancer Center by the National Cancer Institute. With more than 400 clinical trials in progress at any given time, we offer an abundance of opportunities for patients who wish to participate in and benefit from groundbreaking research.
To learn more about our vaginal cancer clinical trials, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. Clinical trial participation does not require a physician referral.
-
Clinical Trials
CLINICAL TRIAL 20870
Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors
Condition: Gynecological Tumor
Intervention: Aspirin/Placebo (); Avastin (Bevacizumab); Bevacizumab (); Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin (); paclitaxel ()
CLINICAL TRIAL 22102
A Phase 1/2, First in Human Multicenter Study of Emi-Le in Patients with Solid Tumors
Condition: Multiple
Intervention: Emiltatug Ledadotin (); XMT-1660 ()
CLINICAL TRIAL 23067
Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-positive Endometrioid Endometrial Cancers
Condition: Gynecological Tumor
Intervention: Alpelisib (); Faslodex (fulvestrant); fulvestrant ()
CLINICAL TRIAL 23143
Trends and Outcomes in HIV-positive Patients Undergoing Treatment for Invasive or Preinvasive Cervical and Other Gynecologic Neoplasias
Condition: Gynecological Tumor
Intervention:
CLINICAL TRIAL 23176
A Phase 2, randomised, open label, multicentre study of an intraperitoneal alpha-emitting radionuclide therapy (Radspherin®) in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer, with peritoneal metastasis that are homologous recombination proficient and scheduled to undergo neoadjuvant chemotherapy and interval debulking surgery
Condition: Gynecological Tumor
Intervention: Radspherin ()
CLINICAL TRIAL 23362
DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer
Condition: Gynecological Tumor
Intervention: Paraplatin (carboplatin); Pembrolizumab (Keytruda); Rilvegostomig (); T-Dxd (); Taxol (paclitaxel); carboplatin (); paclitaxel ()
CLINICAL TRIAL 23380
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod CAR T Protducts in Heterozygous HLA-A*02 Adult with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Condition: Thoracic
Intervention: A2B543 (); A2B694 (); IL-2 (Interleukin-2); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
CLINICAL TRIAL 23636
A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors
Condition: Gynecological Tumor
Intervention: XmAb541 ()
CLINICAL TRIAL 23645
PHASE 1 DOSE ESCALATION AND EXPANSION STUDY OF XB628 AS A SINGLE AGENT AND IN COMBINATION WITH ZANZALINTINIB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Condition: Multiple
Intervention: XB628 (); Zanzalintinib ()
CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Olomorasib (); Sotorasib (); Trametinib (); VVD-159642 ()
CLINICAL TRIAL 24028
OMNIRAY, A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults with GRPR-Positive Advanced Solid Tumors
Condition: Multiple
Intervention: Abemaciclib (); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Exemestane (); Faslodex (fulvestrant); Femara (Letrozole); Imlunestrant (); LY2835219 (Abemaciclib); LY4257496 (); LY4257529 (); Letrozole (); Xeloda (capecitabine); capecitabine (); fulvestrant ()
CLINICAL TRIAL 24081
A Phase 1 Study of SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR, in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma
Condition: Multiple
Intervention: SynKIR-110 ()
CLINICAL TRIAL 24190
A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy with LY4337713 in Adults with FAP-Positive Solid Tumors (FiREBOLT)
Condition: Multiple
Intervention: LY4337713 (); [18F] FAPI-74 (); [Ga-68]-FAPI-46 ()
CLINICAL TRIAL 24236
A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: 5-fluorouracil (); Alimta (Pemetrexed); ERAS-0015 (); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Oxaliplatin (); Panitumumab (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxotere (docetaxel); Vectibix (Panitumumab); carboplatin (); cisplatin (); docetaxel (); eloxatin (Oxaliplatin); gemcitabine (); leucovorin ()
CLINICAL TRIAL 24299
A study of a mutant-selective inhibitor, CGT6297, in patients with advanced solid tumors harboring PIK3CA mutations
Condition: Multiple
Intervention: CGT6297 ()
Treatment